ReviewOne health outlook2025
Assessing rapid response mobile laboratory (RRML) capacities in Europe and Africa to improve One Health disease surveillance activities and pandemic preparedness across two continents.
Review in One health outlook, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role, challenges, and solutions of laboratories in disaster medicine: a systematic review.Frontiers in public health · 2025Pooled it
- Building a One Health mobile laboratory workforce: strengthening public health preparedness across Europe and Africa.Human resources for health · 2026Article
- Ebola Virus Disease in the Era of One Health and Global Preparedness: Evolving Epidemiology, Genomic Surveillance, and Future Challenges.Infectious disease reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEurope and Africa are increasingly affected by (re-)emerging risk group 3 and 4, zoonotic viral disease epidemics, which not only require diagnostic BSL-3/4 laboratory capacity but also a One Health-based control strategy for efficient outbreak containment. In many European and African countries such laboratory capacity is often not readily available, and rapid response mobile laboratories (RRMLs) can play important, complementary roles in outbreak responses and pandemic preparedness activities on national, regional and international level. MAIN BODY: The aim of the present review was to assess whether existing European and African RRML infrastructure is prepared for future One Health outbreak responses and to identify potential diagnostic gaps. Based on a literature review (2007-2021), we identified 291 mobile laboratories (Europe: 192, Africa: 99) and assessed them in respect to purpose (e.g. military, civilian), design (suitcase, modular, vehicle mounted), biosafety level, laboratory equipment, diagnostic portfolio, sample types analyzed (human, animal) and quality assurance measures. Following peaks in 2014 (Ebola/West Africa) and 2020 (COVID-19), mobile laboratory numbers have steadily increased. Whilst laboratories were originally designed to diagnose viral haemorrhagic fevers, there has been an increased focus on SARS-CoV-2 since 2020. Recently, there was a shift of African countries to develop an independent mobile laboratory capacity, rather than relying on external support for outbreak responses.
conclusionWe identified key shortcomings of existing laboratories, as the majority only process samples of human origin (not compliant with One Health principles), only 5% have sufficient capacity to diagnose emerging risk group 3/4 (arbo)viruses, 1-10% have accredited quality assurance systems in place, and mobile laboratories are not interconnected to allow concerted national and international responses. Our results reveal the gaps that should be addressed to make future responses to zoonotic, high-consequence pathogens more effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.